Vertex Pharmaceuticals (VRTX) Earning Favorable News Coverage, Study Shows
News articles about Vertex Pharmaceuticals (NASDAQ:VRTX) have trended positive recently, according to Accern. The research group identifies positive and negative media coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Vertex Pharmaceuticals earned a media sentiment score of 0.29 on Accern’s scale. Accern also gave media coverage about the pharmaceutical company an impact score of 45.8578190108833 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
These are some of the news headlines that may have effected Accern Sentiment Analysis’s analysis:
- Notable Stock’s Stunning Activities: Vertex Pharmaceuticals Incorporated, (NASDAQ: VRTX), 22nd Century Group, Inc … – Stocks In The News (press release) (tradingnewsnow.com)
- Will These Stocks Remain Hot? Vertex Pharmaceuticals Incorporated (VRTX), Celldex Therapeutics, Inc. (CLDX) – Market Movers (financialqz.com)
- Vertex Pharma (VRTX) CRISPR Therapeutics (CRSP) to Co-Develop and Co-Commercialize CTX001 as CRISPR … – StreetInsider.com (streetinsider.com)
- Head to Head Contrast: Vertex Pharmaceuticals (VRTX) vs. Its Rivals (americanbankingnews.com)
- Vertex Pharmaceuticals Inc (VRTX) CEO & President Jeffrey M Leiden Sold $17.7 million of Shares (finance.yahoo.com)
VRTX has been the topic of a number of research analyst reports. DA Davidson initiated coverage on shares of Vertex Pharmaceuticals in a research note on Friday, September 29th. They set a “buy” rating and a $200.00 price objective on the stock. BTIG Research initiated coverage on shares of Vertex Pharmaceuticals in a research note on Friday, September 29th. They set a “buy” rating and a $200.00 price objective on the stock. BMO Capital Markets reiterated a “buy” rating on shares of Vertex Pharmaceuticals in a research note on Wednesday, September 27th. Needham & Company LLC reiterated a “buy” rating and set a $195.00 price objective on shares of Vertex Pharmaceuticals in a research note on Sunday, September 17th. Finally, Vetr lowered shares of Vertex Pharmaceuticals from a “strong-buy” rating to a “buy” rating and set a $181.00 price objective on the stock. in a research note on Monday, September 4th. One research analyst has rated the stock with a sell rating, five have given a hold rating and twenty-three have given a buy rating to the stock. Vertex Pharmaceuticals currently has an average rating of “Buy” and an average target price of $173.15.
Shares of Vertex Pharmaceuticals (NASDAQ:VRTX) traded down $1.93 during trading hours on Tuesday, reaching $141.68. 1,475,100 shares of the company were exchanged, compared to its average volume of 1,792,068. The company has a market capitalization of $36,319.37, a PE ratio of 239.35, a price-to-earnings-growth ratio of 3.44 and a beta of 1.58. Vertex Pharmaceuticals has a 1 year low of $71.46 and a 1 year high of $167.85. The company has a quick ratio of 3.14, a current ratio of 3.28 and a debt-to-equity ratio of 0.01.
Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its earnings results on Wednesday, October 25th. The pharmaceutical company reported $0.53 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.04 by $0.49. The firm had revenue of $578.20 million during the quarter, compared to analysts’ expectations of $522.07 million. Vertex Pharmaceuticals had a net margin of 8.53% and a return on equity of 9.23%. The firm’s revenue for the quarter was up 39.7% compared to the same quarter last year. During the same period last year, the firm posted $0.16 earnings per share. research analysts predict that Vertex Pharmaceuticals will post 0.76 earnings per share for the current fiscal year.
In related news, CMO Jeffrey Chodakewitz sold 3,437 shares of the firm’s stock in a transaction that occurred on Monday, October 2nd. The shares were sold at an average price of $151.64, for a total transaction of $521,186.68. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Michael Parini sold 2,125 shares of the firm’s stock in a transaction that occurred on Thursday, October 12th. The stock was sold at an average price of $152.93, for a total transaction of $324,976.25. The disclosure for this sale can be found here. Insiders have sold 343,519 shares of company stock valued at $49,488,660 over the last 90 days. 1.80% of the stock is currently owned by insiders.
COPYRIGHT VIOLATION NOTICE: “Vertex Pharmaceuticals (VRTX) Earning Favorable News Coverage, Study Shows” was first posted by Watch List News and is the property of of Watch List News. If you are accessing this piece of content on another site, it was stolen and republished in violation of international copyright and trademark law. The legal version of this piece of content can be accessed at https://www.watchlistnews.com/vertex-pharmaceuticals-vrtx-earning-favorable-news-coverage-study-shows/1759979.html.
About Vertex Pharmaceuticals
Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications.
Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.